美股A股
StockGist
Back
6-K2026-03-26· grok-4-1-fast-non-reasoning

AAPG · ASCENTAGE PHARMA GROUP INTERNATIONAL

0001213900-26-034372

SEC filing

Summary

Ascentage Pharma Group International reported full year 2025 unaudited financial results with product sales and commercial rights revenues of US$82.1 million, up 90% year-over-year, driven by Olverembatinib sales of US$62.2 million (up 81%) and Lisaftoclax sales of US$10.1 million since launch, alongside updates on nine ongoing registrational Phase III trials.

Key takeaways